Business Context and Reporting Period
Company: Anteris Technologies Global Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: October 27, 2025
Reporting Period: Single event date (October 27, 2025)
Business Context: The Company is an emerging growth company focused on medical devices, specifically the DurAVR Transcatheter Heart Valve (THV). This filing serves as a Regulation FD disclosure regarding a clinical trial milestone.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is a clinical development milestone rather than a financial variance:
- Clinical Trial Milestone: The Company announced that the first patients have been enrolled and successfully treated in the DurAVR Transcatheter Heart Valve (THV) global pivotal trial.
- Trial Name: PARADIGM Trial.
- Target Population: Patients with severe calcific aortic stenosis.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful initiation of patient treatment in the pivotal trial, indicating progress in the regulatory pathway for the DurAVR THV.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainties of clinical trials. It notes that the information is furnished and not deemed filed for purposes of Section 18 of the Exchange Act unless specifically referenced in a subsequent filing.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the number of patients enrolled and specific trial protocols.
- Confirm the timeline for subsequent enrollment milestones and data readouts for the PARADIGM Trial.
- Review recent 10-K or 10-Q filings for the Company's current cash runway and funding status to support the completion of the pivotal trial.
- Monitor for any future filings that may incorporate this 8-K by reference for regulatory or legal purposes.